Sector: Health Care
Director information for ALKERMES (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Andy Wilson | Lead Independent Director | 67 | [] | ["Audit and Risk","Financial Operating","Nominating and Corporate Governance"] | 2026 |
| Brian P. McKeon | Director; Chair | 64 | ["Strong financial and management expertise","Public company executive and director leadership experience","Experience in finance, strategic planning, corporate development and investor relations","Prior service on public company boards of directors including audit and compensation committees"] | ["Compensation","Financial Operating (C)","Nominating and Corporate Governance","Financial Operating (Chair)","Financial Operating Committee","Nominating and Corporate Governance Committee"] | 2026 |
| Cato T. Laurencin, M.D., Ph.D. | Director | 67 | [] | ["Financial Operating","Financial Operating Committee"] | 2026 |
| Christopher I. Wright, M.D., Ph.D. | Director; Chief Medical Officer | 60 | ["Chief Medical Officer of Wave Life Sciences Ltd.","Chief Medical Officer of Ring Therapeutics, Inc.","Chief Medical Officer of AavantiBio, Inc.","Senior Vice President, Chief Medical Officer of Cyclerion Therapeutics, Inc.","Senior Vice President, Chief Development Officer of Ironwood","Senior Vice President, Chief Medical Officer of Axcella Health Inc.","Senior Vice President of Global Medicines Development and Affairs at Vertex Pharmaceuticals Incorporated","Associate Professor of Neurology at Harvard Medical School","Practicing neurologist at Brigham and Women’s Hospital for 20 years","Scientific Advisor for Cyclerion","Experience in drug development, clinical and medical research"] | ["Audit and Risk","Compensation","Audit and Risk Committee"] | 2026 |
| Frank Anders “Andy” Wilson | Lead Independent Director | ["Former Chief Financial Officer and Senior Vice President of PerkinElmer, Inc.","Oversaw organization's growth strategy","Held key business development and finance roles at Danaher Corporation","Corporate Vice President of Investor Relations at Danaher","Vice President of Finance and Chief Financial Officer at AlliedSignal, Inc.","Financial and controllership positions at PepsiCo, Inc.","Experience with E.F. Hutton and Company and KPMG Peat Marwick","Previously a board member of Sparton Corporation","Certified public accountant","Financial expertise and strategic planning experience"] | ["Audit and Risk","Financial Operating","Nominating and Corporate Governance"] | 2026 | |
| Frank Anders Wilson | ["audit committee financial expert"] | ["Audit and Risk Committee","Financial Operating Committee","Nominating and Corporate Governance Committee"] | 2026 | ||
| Nancy L. Snyderman, M.D. | Independent Director | 74 | ["Oncologic surgeon","Clinical researcher","Consulting professor at Stanford University Center for Innovation in Global Health","Chief Medical Editor at NBC News","Clinical professor of Otolaryngology at the University of Pennsylvania","Senior Vice President Corporate Communications at Johnson & Johnson","Practiced as an Otolaryngologist at UC San Francisco and California Pacific Medical Center","Medical Editor for ABC News","Board member of Lyra Therapeutics, Inc.","Board member of Future Health ESG Corp.","Board member of Axonics, Inc.","Kellogg Fellow","Fellow in the American College of Surgeons","Co-founder of the Stanford University-NBC News Global Media Fellowship"] | ["Audit and Risk","Financial Operating","Audit and Risk Committee","Financial Operating Committee"] | 2026 |
| Nancy S. Lurker | Director; Chair | 68 | ["Broad-ranging experience in the biopharmaceutical industry","Executive leadership","Governance and strategic planning","Expertise in product development and commercialization","Track record of successful U.S. and global product launches","Extensive public company management and board leadership experience","Industry knowledge","Valuable insights with respect to strategy, operations and the development, launch and commercialization of pharmaceutical products"] | ["Compensation","Nominating and Corporate Governance (C)","Nominating and Corporate Governance (Chair)","Nominating and Corporate Governance Committee"] | 2026 |
| Richard B. Gaynor, M.D | Director | 76 | [] | ["Compensation (C)"] | 2026 |
| Richard B. Gaynor, M.D. | Independent Director | ["President, Chief of Research and Development at BioNTech US Inc.","Former President of Research and Development at Neon","Held roles in clinical development and medical affairs at Eli Lilly and Company","Senior Vice President, Clinical Development and Medical Affairs of Lilly Oncology","Faculty at UCLA School of Medicine","Chief of Hematology-Oncology and Director of the Simmons Cancer Center","Published over 140 scientific articles"] | ["Compensation (Chair)"] | 2026 | |
| Richard F. Pops | Director; Chief Executive Officer and Chairman of the Board | 64 | ["Chief Executive Officer of Alkermes, Inc. from February 1991 to April 2007","Chief Executive Officer and President from September 2009 to September 2011","Chairman of the board of directors of the Midsized Biotech Alliance of America","Board member of the Biotechnology Innovation Organization","Board member of the Pharmaceutical Research and Manufacturers of America","Board member of Acceleron Pharma, Inc. from 2004 to December 2019","Board member of Epizyme, Inc. from 2008 to October 2020","Board member of the National Health Council from 2016 to December 2019","Advisory board member of Polaris Venture Partners","Member of the Harvard Medical School Board of Fellows through June 2012","Served on boards of directors of Neurocrine Biosciences, Inc.","Served on boards of directors of Acceleron Pharma, Inc. from 2004 to December 2019","Served on boards of directors of Epizyme, Inc. from 2008 to October 2020","Served on the National Health Council from 2016 to December 2019","Advisory board of Polaris Venture Partners"] | ["Financial Operating","Regulatory Environment Committee","Health Section Governing Board","FDA and Biomedical Research Committee","Financial Operating Committee","MBAA","BIO","PhRMA"] | 2026 |
| Shane M. Cooke | Independent Director; Chair | 63 | ["Served as President of Alkermes Pharma Ireland Limited","Chief Financial Officer of Elan Corporation","Chief Executive of Pembroke Capital Limited","Experience in managing corporate entities in Ireland","Chartered accountant","audit committee financial expert"] | ["Audit and Risk (C)","Financial Operating","Nominating and Corporate Governance","Audit and Risk (Chair)","Audit and Risk Committee","Financial Operating Committee","Nominating and Corporate Governance Committee"] | 2026 |
| Sir Cato T. Laurencin, M.D., Ph.D., K.C.S.L. | INDEPENDENTDirector | ["University Professor and Albert and Wilda Van Dusen Distinguished Endowed Professor of Orthopaedic Surgery at the University of Connecticut","Professor of Chemical and Biomolecular Engineering","Professor of Materials Science and Engineering","Professor of Biomedical Engineering","Chief Executive Officer of The Cato T. Laurencin Institute for Regenerative Engineering at UConn","Former Chief Executive Officer of the Connecticut Convergence Institute for Translation in Regenerative Engineering","Former Vice President for Health Affairs and Dean of the School of Medicine at UConn","Former Orthopaedic Surgeon-in-Chief of the University of Virginia Health System","NACD Directorship Certified"] | ["Financial Operating"] | 2026 |
